THE GLAUCOMA FOUNDATION INC

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

1984

Legal Domicile

Principal Officer

ELENA STURMAN

Phone

2126511900

Tax Period

2025-01-01 to 2025-12-31

THE GLAUCOMA FOUNDATION INC, founded in 1984, is a community nonprofit in the Diseases & Disorders sector that reported $6.0M in total revenue in fiscal year 2025. Revenue surged 32% from the prior year, signaling strong growth momentum. The organization ran a surplus of $2.9M, a strong 49% operating margin.

Mission

THE GLAUCOMA FOUNDATION, INC. IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION DEDICATED TO ERADICATING GLAUCOMA, THE LEADING CAUSE OF PREVENTABLE BLINDNESS. THE STRATEGY TO ACHIEVE THIS GOAL IS TWO-FOLD: RAISE PUBLIC AWARENESS CONCERNING THE NECESSITY OF ROUTINE EYE EXAMS, AND FUND CRITICAL RESEARCH TO FIND CURES FOR GLAUCOMA.

Program Service Accomplishments

Program 1

Expenses: $865,695

1) MULTIPLE WEBINARS: WHAT DO COLD HANDS HAVE TO DO WITH GLAUCOMA? THE PROMISE OF OPTIC NERVE REGENERATION; THE BODY-EYE RELATIONSHIP HOW TO SAVE THE SIGHT OF PATIENTS WITH GLAUCOMA WHILE MINIMIZING ADVERSE REACTION FROM EYE DROPS; INSIGHTS INTO GLAUCOMA & WOMEN'S HEALTH: EXPLORING THE IMPACT OF MENOPAUSE AND VISUAL FUNCTION; GLAUCOMA AND LIFESTYLE. 2) THE OPTIC NERVE RESCUE AND RESTORATION THINK TANK "A PATIENT-CENTRIC APPROACH WHILE INCORPORATING THE LATEST SCIENCE" GLAUCOMA DATA INTEGRATION: OVERVIEW OF DATABASES AVAILABLE TO ADVANCE GLAUCOMA KNOWLEDGE; LESSONS LEARNED ABOUT GLAUCOMA FROM THE UK BIOBANK; POAG GENOMIC ARCHITECTURE; A 360-DEGREE BIOMEDICAL PROFILE OF HEALTH: LESSONS FROM CARDIOVASCULAR DISEASE. 3) DRUG RE-PURPOSING IN GLAUCOMA: INSULIN SIGNALING AND; METFORMIN AND GLAUCOMA; GLP-1R AGONISTS AND GLAUCOMA. 4) OVERVIEW OF GLAUCOMA NEUROPROTECTION AGENTS: WHY DO WE NOT HAVE A NEUROPROTECTION AGENT FOR GLAUCOMA? HOW CAN AI HELP FACILITATE RANDOMIZED CLINICAL TRIALS IN NEUROPROTECTION? 5) SEX HORMONES AND GLAUCOMA: THE ROLE OF SEX HORMONES IN THE PATHOGENESIS OF OPEN-ANGLE GLAUCOMA: EVIDENCE FROM EPIDEMIOLOGICAL STUDIES; ESTROGEN SIGNALING PATHWAYS IN GLAUCOMA; THE BIOMECHANICAL ARGUMENT THAT ESTROGEN PLAYS A ROLE IN GLAUCOMA; 6) NON-IOP FACTORS OF IMPORTANCE IN GLAUCOMA: DIET AND GLAUCOMA; HYPERTENSION, ANTIHYPERTENSIVE DRUGS AND GLAUCOMA; THE IMPACT OF GLAUCOMA ON ACTIVITIES OF DAILY LIVING. 7) WHAT CAN TGF DO TO HELP PATIENTS, RESEARCHERS, AND EYECARE PROVIDERS TACKLE GLAUCOMA?: WHAT IS THE GLAUCOMA FOUNDATION DOING NOW? WHAT DO PATIENTS WANT TO SEE IN GLAUCOMA RESEARCH? 8) START WITH THE YOUNG: INFO SESSION ON GLAUCOMA FOR MIDDLE AND HIGH SCHOOL STUDENTS; IN COORDINATION WITH THE STEM INSTITUTE AT THE CITY COLLEGE OF NEW YORK. 9) NEWSLETTERS: TGF PRODUCED SIX ELECTRONIC NEWSLETTERS THAT WERE DISTRIBUTED TO MORE THAN 16,000 HOUSEHOLDS. TGF'S QUARTERLY PRINTED NEWSLETTERS WERE AVAILABLE FOR CONSTITUENTS WHO DO NOT USE COMPUTERS OR WHO PREFER TO READ PAPER DOCUMENTS. NEWSLETTERS INCLUDE INTERVIEWS WITH DOCTORS, RESEARCHERS, AND PATIENTS. THEY COVER TOPICS SUCH AS ADVANCEMENTS IN DIAGNOSIS AND TREATMENT, PERSPECTIVES ON CARE, AND PERSONAL STORIES OF LIVING WITH THE DISEASE.

Program 2

Expenses: $1,509,236

1) GENETIC PREDISPOSITION AND OPHTHALMIC OUTCOMES; 2) OPTIC NERVE REGENERATION; 3) USING ARTIFICIAL INTELLIGENCE TO REVEAL BLOOD PRESSURE'S ROLE IN GLAUCOMA PROGRESSION; 4) EE-PURPOSING AN "OLD" DRUG FOR A NEW INDICATION: ELUCIDATING THE PERIPHERAL AND CENTRAL EFFECTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS TO TREAT GLAUCOMA; 5) SEARCH FOR FUNCTIONAL LOXL1 RISK ALLELES WITH BIT-STARR; 6) VASCULAR GENOTYPE-PHENOTYPE ASSOCIATION IN PRIMARY OPEN-ANGLE GLAUCOMA; 7) INVESTIGATING THE ROLE OF IMPAIRED MITOCHONDRIAL DYNAMICS IN EXFOLIATION GLAUCOMA; 8) UNCOVERING THE POTENTIAL OF PERICYTES AS THERAPEUTIC TARGETS FOR GLAUCOMA; 9) NICOTINAMIDE AND PYRUVATE FOR NEUROENHANCEMENT IN OPEN-ANGLE GLAUCOMA: A PHASE 2 RANDOMIZED CLINICAL TRIAL.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $5,045,092

Program Service Revenue $0

Investment Income $917,900

Other Revenue $0

TOTAL REVENUE $5,962,992

Expense Breakdown

Grants Paid $982,807

Salaries & Benefits $977,635

Fundraising Expenses $344,659

Program Expenses $2,374,931

Other Expenses $1,080,859

TOTAL EXPENSES $3,058,551

Year-over-Year Comparison

	2025	2024	Change
Revenue	$5,962,992	$4,529,912	+0.3%
Expenses	$3,058,551	$3,072,238	0.0%
Net Income	$2,904,441	$1,457,674	+1.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$444,333

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ELENA STURMAN	PRESIDENT &	40.00	Officer	$421,776	$22,557	$444,333
ELENA CLY FOWKES	DIR OF SPECI	40.00	Highest	$143,934	$22,557	$166,491
ANDREA STEELE	CHIEF OPERAT	40.00	Highest	$120,294	$22,741	$143,035
GREGORY K HARMON	CHAIRMAN	1.00	Officer Director	$0	$0	$0
KENNETH MORTENSON	CHAIR. INV.	1.00	Officer Director	$0	$0	$0
BALDO SCASSELLATI SFORZOLINI	DIRECTOR	1.00	Director	$0	$0	$0
JOHN BERDAHL	DIRECTOR	1.00	Director	$0	$0	$0
REZA DIBADJ	DIRECTOR	1.00	Director	$0	$0	$0
MURRAY FINGERET	DIRECTOR	1.00	Director	$0	$0	$0
DAVID FELLOWS	DIRECTOR	1.00	Director	$0	$0	$0
BARRY S FRIEDBERG	DIRECTOR	1.00	Director	$0	$0	$0
JEFFREY M LIEBMANN	DIRECTOR	1.00	Director	$0	$0	$0
KUMAR MAHADEVA	DIRECTOR	1.00	Director	$0	$0	$0
JAI G PAREKH	DIRECTOR	1.00	Director	$0	$0	$0
PATRICIA HILL	DIRECTOR	1.00	Director	$0	$0	$0
JOE ROSEN	DIRECTOR	1.00	Director	$0	$0	$0
LOUIS PASQUALE	DIRECTOR	1.00	Director	$0	$0	$0
SHELDON M SIEGEL	DIRECTOR	1.00	Director	$0	$0	$0
BARBARA CALABA	DIRECTOR	1.00	Director	$0	$0	$0
CAROLE DARDEN-LLOYD	DIRECTOR	1.00	Director	$0	$0	$0
ALON HARRIS	DIRECTOR	1.00	Director	$0	$0	$0
ANNETTE GROLLMAN	DIRECTOR	1.00	Director	$0	$0	$0
RAJEN SAVJANI	DIRECTOR	1.00	Director	$0	$0	$0
BARBARA HEARST	DIRECTOR	1.00	Director	$0	$0	$0
MITCH HILL	DIRECTOR	1.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$5,962,992	$3,058,551	$20,750,332	$2,904,441
2024	$4,529,912	$3,072,238	$17,585,178	$1,457,674
2023	$4,763,086	$2,878,347	$13,946,604	$1,884,739
2022	$2,913,222	$2,184,741	$12,309,626	$728,481
2021	$4,297,114	$2,530,459	$12,951,160	$1,766,655
2020	$2,437,313	$1,829,799	$9,853,734	$607,514
2019	$3,810,156	$1,913,260	$8,227,674	$1,896,896
2018	$1,462,972	$1,487,081	$6,650,263	$-24,109